
Core Insights - Daxor Corporation has significantly expanded its blood volume analysis capabilities with the introduction of the ezBVA Lab service in three new hospitals, enhancing accessibility and operational efficiency in blood volume measurement [1][2] - The ezBVA Lab service is a CLIA-certified facility that provides precise blood volume analysis results within 24 hours, contributing to strong sales momentum as healthcare providers recognize its clinical and economic benefits [1][2] - Daxor's BVA-100® is the only FDA-cleared diagnostic blood test for quantifying blood volume status and composition, with over 70,000 tests performed, leading to improved hospital performance metrics and reduced mortality and readmissions in heart failure and critical care [3] Recent Developments - The ezBVA Lab service has been adopted by leading healthcare providers, including a regional referral center in Philadelphia, a premier hospital in northern Kentucky, and a community hospital in Arkansas, all focusing on enhancing outpatient heart failure management [5] - Daxor's CEO highlighted the zero-capital investment model and full reimbursement coverage of the ezBVA Lab service as key factors driving its adoption across the nation [2] Company Overview - Daxor Corporation is a leader in blood volume measurement technology, with a mission to advance healthcare through optimal fluid management via blood volume analysis [3] - The company is involved in ongoing trials for heart failure treatment supported by the NIH and is developing analyzers for combat casualty care in collaboration with the U.S. Department of Defense [3]